Published in N Engl J Med on July 20, 2000
RenalGuard System and Contrast Media (REMEDIALII) | NCT01098032
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest (2004) 3.75
Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol (2011) 3.14
Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol (2009) 2.61
Outcome of critically ill patients with acute kidney injury using the Acute Kidney Injury Network criteria. Crit Care Med (2011) 2.11
Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections? Eur Radiol (2012) 2.06
Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol (2008) 1.97
Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol (2008) 1.83
Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. Clin J Am Soc Nephrol (2007) 1.68
A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol (2006) 1.59
Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ (2005) 1.46
Contrast media toxicity in children. Pediatr Radiol (2008) 1.45
N-acetylcysteine-enhanced contrast provides cardiorenal protection. JACC Cardiovasc Interv (2009) 1.44
Risks and complications of coronary angiography: a comprehensive review. Glob J Health Sci (2012) 1.32
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med (2007) 1.19
Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc (2009) 1.16
CKD as an underrecognized threat to patient safety. Am J Kidney Dis (2009) 1.14
Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem (2008) 1.13
Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol (2013) 1.12
N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol (2008) 1.09
N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med (2005) 1.08
In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol (2003) 1.07
Acute kidney injury in the elderly. Clin Geriatr Med (2009) 1.01
Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One (2013) 1.00
Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int (2014) 0.99
Contrast-induced nephropathy; A literature review. J Nephropathol (2014) 0.98
Is cardiac CT a reproducible alternative for cardiac MR in adult patients with a systemic right ventricle? Neth Heart J (2012) 0.98
Nephrology: 4. Strategies for the care of adults with chronic kidney disease. CMAJ (2003) 0.97
Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology (2009) 0.95
Bridging Translation by Improving Preclinical Study Design in AKI. J Am Soc Nephrol (2015) 0.95
Intensive care unit exposures for long-term outcomes research: development and description of exposures for 150 patients with acute lung injury. J Crit Care (2007) 0.94
Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int (2014) 0.93
Complications after endovascular stent-grafting of thoracic aortic diseases. J Cardiothorac Surg (2006) 0.93
N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol (2006) 0.93
Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug. N Engl J Med (2000) 0.92
Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart (2006) 0.91
Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. Biomed Res Int (2013) 0.91
Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study. Crit Care (2012) 0.91
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal (2014) 0.90
The effects of N-acetylcysteine on hepatic function during isoflurane anaesthesia for laparoscopic surgery patients. Indian J Anaesth (2011) 0.88
Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol (2006) 0.88
Prophylaxis of contrast-induced nephrotoxicity. Biomed Res Int (2014) 0.87
Migraine during pregnancy: is it more than a headache? Nat Rev Neurol (2009) 0.87
Treatment of renal calculi by lithotripsy: minimizing short-term shock wave induced renal damage by using antioxidants. Urol Res (2007) 0.86
Management of acute renal failure. Postgrad Med J (2006) 0.86
Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis (2011) 0.86
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med (2004) 0.86
N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart (2005) 0.85
Therapeutic Targets of Human AKI: Harmonizing Human and Animal AKI. J Am Soc Nephrol (2015) 0.85
The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol (2014) 0.85
Low rate of contrast-induced Nephropathy after CT perfusion and CT angiography in acute stroke patients. J Neurol (2007) 0.85
Effect of preoperative N-acetylcysteine on postoperative blood loss parameters in cardiac surgery patients. Int J Vasc Med (2011) 0.84
Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: a systematic review and meta-analysis of randomized controlled trials. N Am J Med Sci (2014) 0.84
Imaging-related medications: a class overview. Proc (Bayl Univ Med Cent) (2007) 0.84
Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur Radiol (2012) 0.84
Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial. Wien Klin Wochenschr (2012) 0.84
Recent hot topics in contrast media. Eur Radiol (2010) 0.83
Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis (2014) 0.83
Update on the diagnosis and management of acute kidney injury. Int J Nephrol Renovasc Dis (2010) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
N-acetylcysteine protects rats with chronic renal failure from gadolinium-chelate nephrotoxicity. PLoS One (2012) 0.82
Contrast-induced nephropathy: attributable incidence and potential harm. Crit Care (2012) 0.82
Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol (2010) 0.82
Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol (2009) 0.82
Pharmacological strategies to prevent contrast-induced acute kidney injury. Biomed Res Int (2014) 0.82
Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol (2011) 0.82
Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol. BMC Clin Pharmacol (2012) 0.81
Contrast medium-induced nephropathy. Aspects on incidence, consequences, risk factors and prevention. Libyan J Med (2007) 0.81
Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients. Crit Care (2005) 0.81
Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur J Clin Pharmacol (2005) 0.81
The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury. NDT Plus (2009) 0.81
Prevention of contrast-induced nephropathy: A randomized controlled trial of sodium bicarbonate and N-acetylcysteine. Int J Angiol (2009) 0.81
Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategies. ISRN Radiol (2013) 0.81
How to protect from contrast media-induced nephropathy? Clin Res Cardiol (2007) 0.80
Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Cardiol Res Pract (2010) 0.80
Preventing contrast-induced nephropathy: problems, challenges and future directions. BMC Med (2009) 0.80
Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Biomed Res Int (2014) 0.80
Contrast-induced nephropathy following angiography and cardiac interventions. Heart (2016) 0.79
Clinical factors associated with dense and wedge-shaped nephrograms detected 24 h after chemoembolization. Cardiovasc Intervent Radiol (2009) 0.79
Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy. J Community Hosp Intern Med Perspect (2015) 0.79
Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study. Korean Circ J (2013) 0.79
Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol (2011) 0.79
Intravenous Hydration and Contrast-Induced Acute Kidney Injury: Too Much of a Good Thing? J Am Heart Assoc (2016) 0.78
NLRP3 inflammasome mediates contrast media-induced acute kidney injury by regulating cell apoptosis. Sci Rep (2016) 0.78
Management of transplant renal artery stenosis. Semin Intervent Radiol (2004) 0.78
Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol (2011) 0.78
N-acetylcysteine protects against renal injury following bilateral ureteral obstruction. Nephrol Dial Transplant (2008) 0.78
Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group. Clin Exp Nephrol (2013) 0.78
The importance of residual renal function in chronic dialysed patients. J Med Life (2010) 0.78
Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol (2013) 0.78
Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography. World J Cardiol (2012) 0.78
Managing chronic renal insufficiency--intertwined roles of non-nephrologist and nephrologist. J Natl Med Assoc (2003) 0.78
Factors associated with the use of preventive care for contrast-induced acute kidney injury. J Gen Intern Med (2009) 0.77
[Contrast induced nephropathy]. Wien Klin Wochenschr (2009) 0.77
N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial. Clin Exp Nephrol (2012) 0.77
Renal-related adverse effects of intravenous contrast media in computed tomography. Singapore Med J (2015) 0.77
A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens (2010) 2.19
Performance of a minimally invasive uncalibrated cardiac output monitoring system (Flotrac/Vigileo) in haemodynamically unstable patients. Br J Anaesth (2008) 1.92
Design and testing of beta-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechniques (1997) 1.54
Diadenosine phosphates and the physiological control of blood pressure. Nature (1994) 1.53
Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol (2006) 1.51
Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation (1997) 1.43
Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci (Lond) (1998) 1.40
Effect of diadenosine polyphosphates on Ca2+ ATPase activity. J Mol Med (Berl) (1997) 1.37
Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int (1991) 1.19
Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J (2000) 1.14
Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med (1997) 1.07
Fulminant disease simulating bacterial sepsis with disseminated intravascular coagulation after a trip to East Africa. Intensive Care Med (2000) 1.03
Use of conventional and self-adjusting nasal continuous positive airway pressure for treatment of severe obstructive sleep apnea syndrome: a comparative study. Chest (1998) 0.99
Regulation of rat mesangial cell growth by diadenosine phosphates. J Clin Invest (1995) 0.99
Effect of continuous positive airway pressure therapy on infectious complications in patients with obstructive sleep apnea syndrome. Respiration (2001) 0.98
Identification and characterization of diadenosine 5',5"'-P1,P2 -diphosphate and diadenosine 5',5"'-P1,P3-triphosphate in human myocardial tissue. FASEB J (1999) 0.97
Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol (1997) 0.96
Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens (2008) 0.96
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics (1996) 0.96
Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur Respir J (2004) 0.95
Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron (1997) 0.93
Filling state of intracellular Ca2+ pools triggers trans plasma membrane Na+ and Ca2+ influx by a tyrosine kinase-dependent pathway. J Biol Chem (1994) 0.93
Validation of the Stabil-O-Graph blood pressure self-measurement device. J Hum Hypertens (2007) 0.92
Right ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J (1997) 0.92
Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes (2000) 0.91
Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest (2003) 0.90
Long-term treatment with continuous positive airway pressure improves quality of life in obstructive sleep apnoea syndrome. Eur Respir J (2000) 0.90
Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiol (Oxf) (2013) 0.90
Intracellular chloride in essential hypertension. Clin Sci (Lond) (1985) 0.89
Identification and characterization of P(1), P(7)-Di(adenosine-5')-heptaphosphate from human platelets. J Biol Chem (1999) 0.88
Dinucleotides as growth-promoting extracellular mediators. Presence of dinucleoside diphosphates Ap2A, Ap2G, and Gp2G in releasable granules of platelets. J Biol Chem (2000) 0.88
Effect of lisinopril and metoprolol on arterial distensibility. Hypertension (1994) 0.87
Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol (2006) 0.87
Intraoperative assessment of kidney allograft perfusion by laser-assisted indocyanine green fluorescence videography. Transplant Proc (2010) 0.87
Activation of Na+, H+ exchanger produces vasoconstriction of renal resistance vessels. Am J Hypertens (1998) 0.87
Adenosine(5') oligophospho-(5') guanosines and guanosine(5') oligophospho-(5') guanosines in human platelets. J Clin Invest (1998) 0.87
Vascular actions of diadenosine phosphates. J Auton Pharmacol (1996) 0.87
Optimized enhancement in helical CT: experiences with a real-time bolus tracking system in 628 patients. Clin Radiol (2000) 0.87
Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. J Mol Med (Berl) (2008) 0.86
Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry (2000) 0.85
Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol (1994) 0.85
Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens (1999) 0.85
Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. Kidney Int (2007) 0.85
Pressure ulcer predictors in ICU patients: nursing skin assessment versus objective parameters. J Wound Care (2008) 0.85
Intracellular Na+ as a genetic marker of essential hypertension. Clin Exp Hypertens (1981) 0.85
Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res (1993) 0.84
[Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism]. Dtsch Med Wochenschr (2007) 0.84
Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney. Br J Pharmacol (1999) 0.84
Elemental mercurial poisoning. South Med J (1997) 0.84
Results of low speed rotational angioplasty for chronic peripheral occlusions. Am J Cardiol (1988) 0.84
Intracellular sodium and calcium in essential hypertension. Klin Wochenschr (1982) 0.83
In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction. Mediators Inflamm (2013) 0.83
Plasma and membrane Ca2+ and Mg2+ concentrations in normal pregnancy and in preeclampsia. Gynecol Obstet Invest (1998) 0.83
Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol (1996) 0.83
Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. J Pharmacol Exp Ther (2001) 0.83
Endovascular irradiation--a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. Int J Radiat Oncol Biol Phys (1994) 0.83
CTF-guided puncture of an unenhanced isodense liver lesion during continuous intravenous injection of contrast medium. Cardiovasc Intervent Radiol (2000) 0.83
Tissue specific activation of the endothelin system in severe acute liver failure. Eur J Med Res (2008) 0.82
Treatment of resistant hypertension by phlebotomy. Klin Wochenschr (1985) 0.82
Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int (2000) 0.82
Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. J Hypertens (1998) 0.82
Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol (1993) 0.82
Captopril and quinapril reduce reactive oxygen species. Eur J Clin Invest (2002) 0.82
Different effects of hypertension, atherosclerosis and hyperlipidaemia on arterial distensibility. J Hypertens (1995) 0.82
Effect of inhibition of sarcoplasmic Ca(2+)-ATPase on vasoconstriction and cytosolic Ca2+ in aortic smooth muscle from spontaneously hypertensive and normotensive rats. Clin Exp Hypertens (1994) 0.82
Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations. J Pharmacol Exp Ther (1999) 0.81
Role of Na(+)-Ca2+ exchange in agonist-induced changes in cytosolic Ca2+ in vascular smooth muscle cells. Am J Physiol (1994) 0.81
Chemoattractant- and mitogen-induced generation of reactive oxygen species in human lymphocytes: the role of calcium. Exp Physiol (1999) 0.81
Benign intracranial hypertension in an HIV-infected patient: headache as the only presenting sign. AIDS (1995) 0.81
Albuminuria in HIV-infected patients. AIDS Res Hum Retroviruses (1994) 0.81
Evidence of altered homocysteine metabolism in chronic renal failure. Nephron (1999) 0.81
Transforming growth factor beta 1 modulates angiotensin II-induced calcium influx in vascular smooth muscle. Eur J Clin Invest (1995) 0.81
Beta-blockers do not impair the cardiovascular benefits of endurance training in hypertensives. J Hum Hypertens (2007) 0.81
A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. J Vasc Res (1992) 0.81
Transdermal beta-blocker therapy in essential hypertension. Am J Hypertens (1988) 0.81
Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes. J Biol Chem (1997) 0.81
Sodium reabsorption in the isolated perfused kidney of normotensive and spontaneously hypertensive rats. J Hypertens Suppl (1989) 0.81
Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. J Hum Hypertens (2012) 0.81
Non-receptor-mediated activation of IK(ATP) and inhibition of IK(ACh) by diadenosine polyphosphates in guinea-pig atrial myocytes. J Physiol (1998) 0.81
Impaired renal allograft function is associated with increased arterial stiffness in renal transplant recipients. Am J Transplant (2006) 0.80
The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to P(2X)-receptors in the isolated perfused rat kidney. Br J Pharmacol (2001) 0.80
Reduced distensibility of the common carotid artery in patients treated with ergotamine. Hypertension (1996) 0.80
Circadian blood pressure variations in endocrine disorders. Blood Press (1993) 0.80
Expandable tubular stents for treatment of arterial occlusive diseases: experimental and clinical results. Work in progress. Radiology (1990) 0.80
Identification of dinucleoside polyphosphates by matrix-assisted laser desorption/ionisation post-source decay mass spectrometry. Rapid Commun Mass Spectrom (2003) 0.80
High-performance liquid chromatographic assay of the diadenosine polyphosphates in human platelets. Anal Biochem (1999) 0.80